We expect that as solid tumor-specific CARs are developed, the combination of CAR T cells and IDO1 inhibition by miRNAs or other pharmacological approaches will be an effective treatment option for colorectal cancer and other solid tumors. The gene discussed is IDO1; the disease is colorectal cancer.